$5.57+0.07 (+1.27%)
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases.
Passage Bio, Inc. in the Healthcare sector is trading at $5.57. Wall Street consensus targets $11.40 (5 analysts), implying a +104.7% move over the next 12 months. The stock is currently near its 52-week low of $3.94, remaining 34.2% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficienc...
Passage Bio Inc (NASDAQ:PASG) is one of the best gene therapy stocks to buy in 2026. While the stock is down around 50% year-to-date, analysts see it surging 125% over the next 12 months. On April 20, Passage Bio said it was reviewing its strategic alternatives to maximize shareholder value. It has tapped Wedbush PacGrow […]
Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index down 1% and the
Passage Bio (PASG) faces a tougher path after US regulators told the company it will need to run a r
Passage Bio (PASG) is "undervalued" given PBFT02's distinct profile, with the US Food and Drug Admin
Intel upgraded, Reddit initiated: Wall Street's top analyst calls